Onxeo : Press Release

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX
Copenhagen: ONXEO) is an innovative company specializing in the development of
orphan oncology drugs.

Articles posted on the internet refer to a social restructuring project at
Therabel Lucien Pharma laboratory - a subsidiary of the Dutch group Therabel –
ONXEO’s (Euronext Paris, Nasdaq, OMX Copenhagen – ONXEO) partner for the
commercialization of Loramyc® in Europe.

ONXEO cannot comment on this project at this time and it should be considered
that the terms of the agreement remain unchanged.

As ONXEO has focused its growth strategy on medicines treating orphan oncology,
Loramyc® is not a strategic product for the company, does not significantly
contribute to its revenues nor results, and should not be considered as a
significant factor in its valuation.

All information related to Loramyc®, including any change to its distribution
channel, will be the subject of a communication in reference documents and semi
-annual publications.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad® ): Phase II in severe oral mucositis: Positive
preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

Loramyc® is marketed through partnership agreements in Europe with the Therabel
Group, in Southeast Asia with Handok, in China with SciClone Pharmaceuticals, in
Japan with Sosei and in Iran with Shafayab Gostar.

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
Contacts
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol / Sophie Colin – Alize RP
caroline@alizerp.com / scolin@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62